ÁREA: NEUROCIENCIAS

Objectives and lines of research
Objectives
During the last 15 years our activity has been focused on studying the mechanisms responsible for the degeneration of dopaminergic neurons and the development of new therapeutic strategies.
The study is approached from several lines of research:
• Neuroprotection of dopaminergic neurons
• Role of the cerebral Renin Angiotensin System in dopaminergic degeneration.
• In vitro generation of dopaminergic neurons from neural stem cells or induced pluripotent stem cells (iPs) to drive cell therapy in Parkinson’s disease.
• Pharmacological approach to dyskinesias.
• Search for biomarkers of onset and progression of Parkinson’s Disease.
Lines of research
• Development of neuroprotection strategies in in vivo and in vitro models of dopaminergic degeneration.
• Development of methods for the proliferation and differentiation of dopaminergic neurons from stem cells or neural stem cells for cell therapy in animal models of Parkinson’s disease.
• Pharmacological approach to dyskinesias.
• Search for biomarkers of onset/progression of Parkinson’s disease.
Research team
Projects
Publications
- Garcia-Garrote, M., Parga, J. A., Labandeira, P. J., Labandeira-Garcia, J. L., & Rodriguez-Pallares, J. (2021). Dopamine regulates adult neurogenesis in the ventricular-subventricular zone via dopamine D3 angiotensin type 2 receptor interactions. Stem Cells, 39(12), 1778-1794. doi:10.1002/stem.3457
- Valenzuela, R., Rodriguez-Perez, A. I., Costa-Besada, M. A., Rivas-Santisteban, R., Garrido-Gil, P., Lopez-Lopez, A., Navarro, G., Lanciego, J. L., Franco, R., & Labandeira-Garcia, J. L. (2021). An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria. Redox Biol, 46, 102078. doi:10.1016/j.redox.2021.102078
- Rodriguez-Perez, A. I., Labandeira, C. M., Pedrosa, M. A., Valenzuela, R., Suarez-Quintanilla, J. A., Cortes-Ayaso, M., Mayan-Conesa, P., & Labandeira-Garcia, J. L. (2021). Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun, 122, 102683. doi:10.1016/j.jaut.2021.102683
- Valenzuela, R., Pedrosa, M. A., Garrido-Gil, P., Labandeira, C. M., Navarro, G., Franco, R., Rodriguez-Perez, A. I., & Labandeira-Garcia, J. L. (2021). Interactions between ibuprofen, ACE2, renin-angiotensin system, and spike protein in the lung. Implications for COVID-19. Clin Transl Med, 11(4), e371. doi:10.1002/ctm2.371
- Pedrosa, M. A., Valenzuela, R., Garrido-Gil, P., Labandeira, C. M., Navarro, G., Franco, R., Labandeira-Garcia, J. L., & Rodriguez-Perez, A. I. (2021). Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci (Lond), 135(3), 465-481. doi:10.1042/CS20201511
- Lopez-Lopez, A., Labandeira, C. M., Labandeira-Garcia, J. L., & Munoz, A. (2020). Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson’s disease. Br J Pharmacol, 177(24), 5622-5641. doi:10.1111/bph.15275
- Rodriguez-Perez, A. I., Garrido-Gil, P., Pedrosa, M. A., Garcia-Garrote, M., Valenzuela, R., Navarro, G., Franco, R., & Labandeira-Garcia, J. L. (2020). Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra. Brain Behav Immun, 87, 256-271. doi:10.1016/j.bbi.2019.12.011
- Seoane-Collazo, P., Linares-Pose, L., Rial-Pensado, E., Romero-Pico, A., Moreno-Navarrete, J. M., Martinez-Sanchez, N., Garrido-Gil, P., Iglesias-Rey, R., Morgan, D. A., Tomasini, N., Malone, S. A., Senra, A., Folgueira, C., Medina-Gomez, G., Sobrino, T., Labandeira-Garcia, J. L., Nogueiras, R., Domingos, A. I., Fernandez-Real, J. M., Rahmouni, K., Dieguez, C., & Lopez, M. (2019). Central nicotine induces browning through hypothalamic kappa opioid receptor. Nat Commun, 10(1), 4037. doi:10.1038/s41467-019-12004-z